WHAT IS CLAIMED IS:

1. An orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein:

the pellets comprise a core, a release coating, and an enteric coating; and where

the core comprises acamprosate calcium and a diluent; and the release coating comprises an hydroxypropyl methylcellulose (HPMC); and the enteric coating comprises a polymer of methacrylic acid or a derivative thereof.

2. The formulation of claim 1 wherein the diluent comprises a microcrystalline cellulose (MCC) or a cellulose gel.

3. The formulation of claim 1 or claim 2, wherein the core comprises about 30% to about 80% acamprosate calcium by weight.

4. The formulation of any one of claims 1-3, wherein the release coating comprises a thermoplastic cellulose ether other than an ethyl cellulose, or a mixture of one or more thermoplastic cellulose ethers and an ethyl cellulose.

5. The formulation of claim 4, wherein the release coating comprises an HPMC, or a mixture of HPMC and an ethyl cellulose.

6. The formulation of claim 5, wherein the release coating comprises a mixture of HPMC and an ethyl cellulose, where the ratio of HPMC to the ethyl cellulose is about 4.5 to about 0.5 by weight.

7. The formulation of claim 5, wherein the release coating comprises a mixture of HPMC and an ethyl cellulose where the ratio of HPMC to the ethyl cellulose is about 1 or greater by weight.

8. The formulation of any one of claims 1-7, wherein the enteric coating comprises an anionic polymer.

9. The formulation of claim 8, wherein the anionic polymer is a polymer or copolymer comprising acrylate and/or methacrylate radicals, and esters thereof.

10. The formulation of claim 9, wherein the enteric coating is a copolymer of methacrylic acid and methyl methacrylate.

11. The formulation of claim 10, wherein the ratio of acid residues to ester residues is in the range from about 1:3 to about 3:1.

12. The formulation of claim 10, wherein the ratio of acid residues to ester residues is in the range from about 1:2 to about 1:1.

13. The formulation of any one of claims 1-12 comprising at least about 30% acamprosate calcium by weight.

14. The formulation of any one of claims 1-13 comprising at least about 0.1%HPMC by weight.

15. The formulation of claim 14 comprising at least about 1% HPMC by weight.

16. The formulation of claim 15 comprising at least about 2% HPMC by weight.

17. The formulation of any one of claims 1-16 comprising less than 5% of an ethyl cellulose by weight.

18. The formulation of claim 17 comprising less than 4% of an ethyl cellulose by weight.

19. The formulation of any one of claims 1-18 comprising less than 30% anionic polymer by weight.

20. The formulation of any one of claims 1-19 comprising less than 4000 ppm total organic solvent.

21. Use of the formulation of any one of claims 1 to 20 in the manufacture of a medicament for treating one or more autism spectrum disorders in a patient.

22. The use of claim 21 wherein the autism spectrum disorders are selected from the group consisting of autism, Pervasive Development Disorder-Not Otherwise Specified, Idiopathic Autism, Fragile X Syndrome, Asperger's Syndrome, Rhett's Syndrome, and Heller's syndrome.